

---Supporting information---

## Concise Synthesis of Azilect via Cobalt-Catalyzed Enantioselective Hydrogenation in Bio-based Solvent

Soumyadeep Chakraborty,<sup>a</sup> Felix J. de Zwart,<sup>b</sup> Demi D. Snabilié,<sup>b</sup> Ekambaram Balaraman,<sup>c</sup> Joost N. H. Reek,<sup>b</sup> Bas de Bruin,<sup>b</sup> Johannes G. de Vries\*<sup>a</sup>

<sup>[a]</sup> Soumyadeep Chakraborty, Ekambaram Balaraman, Johannes G. de Vries

Leibniz Institute for Catalysis e.V.

Albert-Einstein-Strasse 29a, 18059 Rostock

Email: [Johannes.deVries@catalysis.de](mailto:Johannes.deVries@catalysis.de)

<sup>[b]</sup> Felix J. de Zwart, Demi D. Snabilié, Joost N. H. Reek, Bas de Bruin

Van't Hoff Institute for Molecular Sciences (HIMS), Science Park 904,

1098 XH Amsterdam, The Netherlands.

<sup>[c]</sup> Department of Chemistry, Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati - 517507, Andhra Pradesh, India.

### Table of Contents

<b>1. General information</b> .....	2
<b>2. Indanone derived carbocyclic enamide synthesis and analytical data</b> .....	3
<b>3. Additional reaction optimization parameters</b> .....	15
<b>4. General procedure for asymmetric hydrogenation (AH)</b> .....	19
<b>5. Synthesis of Co-BPE complexes</b> .....	20
<b>6. EPR experiments for mechanistic studies</b> .....	23
<b>7. Analytical data of the indanone-amides</b> .....	26
<b>8. Synthetic protocol for Rasagiline synthesis</b> .....	37
<b>9. Deuteration of 1a and analytical data</b> .....	42
<b>10. Chiral HPLC traces</b> .....	46
<b>11. Chiral GC traces</b> .....	62

## 1. General information

### **Chemical and solvents**

All the reactions have been carried out using standard Schlenk techniques or under inert atmosphere in N<sub>2</sub> – filled glove box, unless noted otherwise. All the chemicals used were commercial grade and utilized without further purifications. All the chiral ligands have been purchased from Strem chemicals and directly used for further catalytic reactions. 2-Me THF was purchased from Merck (anhydrous and inhibitor free) and directly used for catalysis. All the other solvents were pre-dried with Solvent Purification System (SPS) from MBraun (MB SPS-800, with standard MBraun drying columns) as required. All the solvents were stored on activated 3 Å molecular sieves and degassed by sparging with argon before using in catalysis.

### **NMR spectroscopy**

NMR spectra were recorded on Bruker Avance 300 (<sup>1</sup>H: 300, <sup>13</sup>C: 75, <sup>31</sup>P: 121 MHz), Bruker Fourier 300 (<sup>1</sup>H: 300, <sup>13</sup>C: 75, <sup>31</sup>P: 121 MHz) or Avance 400 (<sup>1</sup>H: 400, <sup>13</sup>C: 100, <sup>31</sup>P: 161 MHz) instruments operating at the denoted spectrometer frequency given in megahertz (MHz) for the specified nucleus.

### **EPR spectroscopy**

EPR measurements were performed in air-tight high-pressure tube (Wilmad 734-PV-7) in an atmosphere of purified argon. Frozen solution EPR spectra were recorded on a Bruker EMX-plus CW X-band spectrometer equipped with a Bruker ER 4112HV-CF100 helium cryostat.

### **High performance liquid chromatography (HPLC)**

The chiral amides have been analyzed with chiral column in Agilent 1200 series HPLC. Method and column information have already been described in the HPLC traces.

### **Gas chromatography (GC)**

The samples have been analyzed with Agilent HP6890 instrument with FID detector and a column. *HP5* (30 m x 250 mm x 0.25 μm): Front Injector Syringe Size 10 μL, Syringe 10 μL Agilent G4513-80203, Injection Volume 1 μL, Front SS Inlet He, Mode Split Heater On 250 °C

Pressure On 0.60993 bar, Total Flow On 86.971 mL/min, Septum Purge Flow On 3 mL/min  
Pressure 0.60993 bar, Flow 1.6465 mL/min, Average Velocity 29.749 cm/sec Run Time 33.5  
min

CP-Chirasil-Dex CB (25.955m x 320  $\mu$ m x 0.25  $\mu$ m): Flow 3 mL/min, Pressure 13.698 psi, Avg  
vel. 51.506 cm/sec, Initial 100 °C-hold 5 min, ramp (5 °C/min) 150 °C-hold 30 min, ramp (5  
°C/min) 180 °C-hold 5°C, runtime 56 min

## 2. Indanone derived carbocyclic enamide synthesis and analytical data




Figure S 1 General procedure for substrate synthesis


**Indanone-enamide synthesis:** Using the Ti-method (Ref. J. T. Reeves, Z. Tan, Z. S. Han, G. Li, Y. Zhang, Y. Xu, D. C. Reeves, N. C. Gonnella, S. Ma, H. Lee, B. Z. Lu and C. H. Senanayake, *Angew. Chem. Int. Ed.*, 2012, 51, 1400-1404. )

To a dry 50 mL Schlenk flask equipped with a magnetic stir bar was charged indanone derivative (1.17 mL, 10.0 mmol, 1 equiv.) and toluene (5 mL). The resultant solution was stirred and cooled in an

ice/water bath. To the cold stirring solution was added 7N NH<sub>3</sub> in MeOH (2.14 mL, 15.0 mmol, 1.5 equiv.) followed by dropwise addition of Ti(Oi-Pr)<sub>4</sub> (5.92 mL, 20.0 mmol, 2.0 equiv.) maintain the inert conditions. After 10 min, the ice/water cooling bath was removed, and the solution was stirred at rt for 18-24 h. The reaction mixture was then cooled in an ice/water bath (~5 °C) and treated with Et<sub>3</sub>N (5.58 mL, 40.0 mmol, 4.0 equiv.) followed by Ac<sub>2</sub>O (1.89 mL, 20.0 mmol, 2.0 equiv.). The cooling bath was then removed, and the solution was stirred at rt for 1-3 h. The reaction mixture was then treated with EDTE (4.51 mL, 21.0 mmol, 2.1 equiv.) at rt, and the solution was then heated at about 55 °C for 15 min. The reaction mixture was allowed to cool to rt and was then poured into a separatory funnel containing a solution made from water (30 mL) and NH<sub>4</sub>OH (10 mL) and also EtOAc (50 mL). Additional water and EtOAc were used to rinse all the flask contents into the separatory funnel. The mixture was shaken, and from the resultant two clear phases the lower aqueous phase was removed. The aqueous phase was extracted in dichloromethane or ethyl acetate. The combined organic extracts were dried (MgSO<sub>4</sub>), filtered, and concentrated to give the crude product (as mostly dark solid). Purification by flash chromatography on SiO<sub>2</sub> (hexanes/EtOAc, 90:10 to 60:40) gave the corresponding enamides (1.31 g, 60-75% yield). The isopropyl and phenyl derivative can easily be synthesized upon using the corresponding anhydride derivatives.

**Analytical data of the enamides:**

▪ ***N-(1H-inden-3-yl)acetamide***



**<sup>1</sup>H NMR** (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ; 7.70 (br, 1H), 7.50-7.48 (m, 1H), 7.38-7.23 (m, 2H), 6.83 (t, J = 2.47 Hz, 1H), 3.43 (dd, J = 2.44 Hz, 2H), 2.21 (s, 3H).

**<sup>13</sup>C NMR** (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ; 168.66, 142.90, 139.79, 125.94, 125.36, 124.19, 116.31, 115.27, 36.48, 23.93.

**HRMS:** m/z calculated for C<sub>11</sub>H<sub>11</sub>NO: 174.21 [M+H]<sup>+</sup>; observed 174.31.




Figure S 2  $^1\text{H NMR}$  of 1a





Figure S 3  $^{13}\text{C NMR}$  of 1a


▪ ***N*-(5-methoxy-1*H*-inden-3-yl)acetamide**



<sup>1</sup>H NMR (300 MHz, DMSO) δ; 9.69 (br, 1H), 7.45 (d, J = 2.40 Hz, 1H), 7.32 (dd, J = 8.23 Hz, 1H), 6.80-6.76 (m, 2H), 3.80 (s, 3H), 3.38 (s, 1H), 3.29-3.28 (m, 2H), 2.13 (s, 3H).

<sup>13</sup>C NMR (75 MHz, DMSO) δ; 169.27, 158.88, 141.86, 137.04, 134.64, 124.73, 115.42, 111.67, 104.36, 55.78, 55.57, 35.60, 23.98, 23.33, 14.53.

**HRMS:** m/z calculated for C<sub>12</sub>H<sub>13</sub>NO<sub>2</sub>: 204.29 [M+H]<sup>+</sup>; observed 204.26







Figure S 5  $^{13}\text{C}$  NMR of 4a

■ ***N*-(6-methoxy-1*H*-inden-3-yl)acetamide**



$^1\text{H}$  NMR (300 MHz, DMSO)  $\delta$ : 9.68 (br, 1H), 7.66 (d,  $J$  = 8.43 Hz, 1H), 7.08 (s, 1H), 6.90 (dd,  $J$  = 8.41 Hz), 6.59 (m, 1H), 3.77 (s, 3H), 3.36 (m, 2H), 2.11 (s, 3H).

$^{13}\text{C}$  NMR (75 MHz, DMSO)  $\delta$ : 169.25, 158.33, 144.72, 136.76, 133.50, 119.12, 112.00, 111.92, 110.69, 55.70, 36.34, 23.95.

HRMS:  $m/z$  calculated for  $\text{C}_{12}\text{H}_{13}\text{NO}_2$ : 204.37  $[\text{M}+\text{H}]^+$ ; observed 204.31




Figure S 6 <sup>1</sup>H NMR of 5a





Figure S 7 <sup>13</sup>C NMR of 5a



▪ ***N*-(6-fluoro-1*H*-inden-3-yl)acetamide**



$^1\text{H NMR}$  (300 MHz, DMSO)  $\delta$ ; 9.77 (br, 1H), 7.76 (dd,  $J = 8.48$  Hz, 1H), 7.31 (dd,  $J = 9.04$  Hz, 1H), 7.16 (m, 1H), 6.73 (br, 1H), 3.37 (s, 3H), 2.12 (2H).

$^{13}\text{C NMR}$  (75 MHz, DMSO)  $\delta$ ; 169.35, 163.03, 159.84, 145.40, 145.28, 136.84, 136.81, 136.43, 119.70, 119.59, 114.18, 114.13, 113.27, 112.97, 112.09, 111.79, 36.46, 36.43, 23.92.

**HRMS:**  $m/z$  calculated for  $\text{C}_{10}\text{H}_{10}\text{FNO}$ : 192.19  $[\text{M}+\text{H}]^+$ ; observed 192.25




Figure S 8  $^1\text{H NMR}$  of 6a





Figure S 9  $^{13}\text{C}$  NMR of 6a

▪ ***N*-(6-bromo-1*H*-inden-3-yl)acetamide**



$^1\text{H}$  NMR (300 MHz, DMSO)  $\delta$ : 9.79 (br, 1H), 7.72 (d,  $J$  = 8.19 Hz, 1H), 7.64-7.63 (m, 1H), 7.54-7.50 (m, 1H), 3.38 (s, 3H), 2.12 (s, 2H).

$^{13}\text{C}$  NMR (75 MHz, DMSO)  $\delta$ : 169.37, 145.40, 139.79, 136.58, 129.16, 127.37, 120.45, 118.98, 115.01, 36.41, 23.91.

HRMS:  $m/z$  calculated for  $\text{C}_{11}\text{H}_{10}\text{BrNO}$ : 253.19  $[\text{M}+\text{H}]^+$  ; observed 253.36




Figure S 10  $^1\text{H}$  NMR of 7a





Figure S 11  $^{13}\text{C}$  NMR of 7a

▪ *N*-(1*H*-inden-3-yl)isobutyramide



$^1\text{H NMR}$  (300 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 7.54 (br, 1H), 7.51-7.48 (m, 1H), 7.33-7.30 (m, 2H), 7.29-7.23 (m, 1H), 6.85 (br, 1H), 3.43 (dd,  $J = 2.41$  Hz, 2H), 1.25 (d,  $J = 6.87$  Hz, 6H).

$^{13}\text{C NMR}$  (75 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$ : 175.48, 142.93, 139.85, 135.65, 125.91, 125.37, 124.21, 116.16, 115.17, 36.50, 36.18, 19.47.

**HRMS:**  $m/z$  calculated for  $\text{C}_{13}\text{H}_{15}\text{NO}$ : 202.36  $[\text{M}+\text{H}]^+$ ; observed 202.38




Figure S 12  $^1\text{H NMR}$  of 2a





Figure S 13 <sup>13</sup>C NMR of 2a

▪ ***N*-(1*H*-inden-3-yl)benzamide**



**<sup>1</sup>H NMR** (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ; 8.04 (br, 1H), 7.93-7.90 (m, 2H), 7.63-7.51 (m, 5H), 7.38-7.36 (m, 2H), 7.32-7.27 (m 1H), 7.00 (t, J = 2.42 Hz, 1H), 3.51 (dd, J = 2.47 Hz, 2H).

**<sup>13</sup>C NMR** (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ; 165.51, 142.96, 139.75, 135.60, 134.65, 131.89, 128.83, 126.99, 126.01, 125.54, 124.33, 116.09, 115.86, 36.64.

**HRMS:** m/z calculated for C<sub>16</sub>H<sub>13</sub>NO: 236.34 [M+H]<sup>+</sup> ; observed 236.39




Figure S 14 <sup>1</sup>H NMR of 3a




Figure S 15 <sup>13</sup>C NMR of 3a

### 3. Additional reaction optimization parameters






Figure S 16 Additional ligand screened in this work



Entry	Ligand	Solvent	Conversion	Enantiomeric excess
1	(S,S)-PhBPE	MeOH	-	
2	(S,S)-PhBPE	i-PrOH	>99%	52:47
3	(S,S)-PhBPE	tert-BuOH	75%	75:25
4	(S,S)-PhBPE	TFE	-	-
5	(R,R)-QunioxP*	MeOH	-	-
6	(R,R)-QunioxP*	i-PrOH	-	-
7	(R,R)-QunioxP*	tert-BuOH	-	-
8	(R,R)-QunioxP*	TFE	-	-

Reaction condition: [Co (stearate)<sub>2</sub>] (5 mol%), Ligand (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL) , H<sub>2</sub> (60 bar), temperature = 60°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.


Table S 1 Optimization using [Co (stearate)<sub>2</sub>]/bisphosphines



Entry	Ligand	Solvent	Conversion	Enantiomeric excess
1	( <i>S,S</i> )- <sup>Ph</sup> BPE	MeOH	70%	30:70
2	( <i>S,S</i> )- <sup>Ph</sup> BPE	i-PrOH	-	-
3	( <i>S,S</i> )- <sup>Ph</sup> BPE	tert-BuOH	-	-
4	( <i>S,S</i> )- <sup>Ph</sup> BPE	TFE	-	-
5	( <i>S,S</i> )- <sup>Me</sup> DuPhos	MeOH	-	-
6	( <i>S,S</i> )- <sup>Me</sup> DuPhos	i-PrOH	-	-
7	( <i>S,S</i> )- <sup>Me</sup> DuPhos	tert-BuOH	-	-
8	( <i>S,S</i> )- <sup>Me</sup> DuPhos	TFE	-	-
9	( <i>R,R</i> )-QunioxP*	MeOH	-	-
10	( <i>R,R</i> )-QunioxP*	i-PrOH	-	-
11	( <i>R,R</i> )-QunioxP*	tert-BuOH	-	-
12	( <i>R,R</i> )-QunioxP*	TFE	-	-

Reaction condition:  $[CoCl_2]$  (5 mol%), Ligand (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL),  $H_2$  (60 bar), temperature = 60°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.

Table S 2 Optimization using  $[CoCl_2]$ /bisphosphines




Entry	Ligand	Solvent	Conversion	Enantiomeric excess
1	$NiCl_2$	MeOH	70%	30:70
2	$NiBr_2$	MeOH	-	-
3	$Ni(OTf)_2$	MeOH	-	-
4	$FeBr_2$	MeOH	-	-



5	FeCl <sub>2</sub>	MeOH	-	-
6	MnCl <sub>2</sub>	MeOH	-	-
7	Mn(CO) <sub>5</sub> Br	MeOH	-	-

Reaction condition: [M] (5 mol%), (S,S)-PhBPE (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL), H<sub>2</sub> (60 bar), temperature = 60°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.


Table S 3 Optimization using other 1<sup>st</sup> row metals/bisphosphines



Entry	Ligand	Solvent	Conversion	Enantiomeric excess
1	(S,S)-PhBPE	MeOH	>99%	10:90
2	(S,S)-PhBPE	TFE	25%	8:92
3	(S,S)-MeDuPhos	MeOH	60%	60:40
4	(S,S)-MeDuPhos	TFE	-	-

Reaction condition: [CoCl<sub>2</sub>] (5 mol%), Ligand (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL), H<sub>2</sub> (60 bar), temperature = 60°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.


Table S 4 Optimization using Zn-additive



Entry	Solvent	Conversion	Enantiomeric excess
1	MeOH	90%	13:87
2	i-PrOH	40%	16:84
3	2-MeTHF	>99%	6:94
4	1-BuOH	90%	9:91

Reaction condition:  $[\text{Co}(\text{OTf})_2]$  (5 mol%), (*S,S*)-<sup>Ph</sup>BPE (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL),  $\text{H}_2$  (50 bar), temperature = 40°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.


Table S 5 Optimization using other solvents and temperature



Entry	Ligand	Solvent	Conversion	Enantiomeric excess
1	( <i>S,S</i> )- <sup>Ph</sup> BPE	MeOH	40%	9:91
2	( <i>S,S</i> )- <sup>Ph</sup> BPE	i-PrOH	20%	6:94
3	( <i>S,S</i> )- <sup>Ph</sup> BPE	2-MeTHF	98%	8:92
4	( <i>S,S</i> )- <sup>Ph</sup> BPE	1-BuOH	90%	7:93
5	( <i>R,R</i> )- <sup>iPr</sup> BPE	MeOH	20%	n.d.
6	( <i>R,R</i> )- <sup>iPr</sup> BPE	i-PrOH	-	-
7	( <i>R,R</i> )- <sup>iPr</sup> BPE	2-MeTHF	70%	92:8
8	( <i>R,R</i> )- <sup>iPr</sup> BPE	1-BuOH	50%	91:9

Reaction condition:  $[\text{Co}]$  (5 mol%), Ligand (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL),  $\text{H}_2$  (50 bar), temperature = rt, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC.

Table S 6 Detailed solvent effect using  $\text{CoCl}_2$  as metal precursor




Entry	Solvent	$\text{H}_2$ (bar)	Conversion	Enantiomeric excess
1	MeOH	40 bar	>99%	10:90
2	2-MeTHF	40 bar	>99%	8:92
3	MeOH	30 bar	>99%	9:91

4	2-MeTHF	30 bar	>99%	9:91
5	MeOH	20 bar	>99%	9:91
6	2-MeTHF	20 bar	>99%	7:93
7	MeOH	10 bar	>99%	10:90
8	2-MeTHF	10 bar	>99%	6:94
9	MeOH	5 bar	80%	10:90
10	2-MeTHF	5 bar	>99%	6:94
11 <sup>a</sup>	MeOH	10 bar	-	-
12 <sup>a</sup>	2-MeTHF	10 bar	90%	6:94
13 <sup>b</sup>	2-MeTHF	30 bar	30%	30:70

Reaction condition: [Co(OTf)<sub>2</sub>] (5 mol%), (S,S)-<sup>Ph</sup>BPE (5 mol%), [substrate]= 0.1 mmol, solvent (2 mL), H<sub>2</sub> (as desired), temperature = 50°C, reaction time = 22 hrs. Conversion determined by GC and NMR analysis. Enantiomeric ratio was determined by chiral GC. <sup>a</sup>at room temperature. <sup>b</sup>without Zn

Table S 7 Detailed solvent effect using Co(OTf)<sub>2</sub> as metal precursor as different conditions

#### 4. General procedure for asymmetric hydrogenation (AH)




Scheme S 1 General protocol for Co-catalyzed asymmetric hydrogenation of indanone derived enamides

All the hydrogenation experiments were performed in a stainless steel autoclave charged with an insert suitable for up to 8 reaction vessels (4 mL) with teflon mini stirring bars. In a typical experiment, a reaction vessel is charged with [Co]-precursors (5 mol%) and ligand (5 mol%) and stirred for 10-15 mins in the appropriate solvent (2mL). Then the additive Zn (50 mol%) and desired substrates **Xa** (0.2 mmol) were added to the reaction vessel maintaining the inert atmosphere and the vessels were placed in the autoclave. The autoclave was purged two times with nitrogen and three times with hydrogen. Finally it was pressurized at the desired H<sub>2</sub> pressure at 50°C/60°C (as needed) for 22 h. After the required reaction time, the autoclave was depressurized and the reaction vessels were diluted with

EtOAc and filtered through a short pad of silica. The conversion was determined by GC, GC-MS and NMR measurement and the enantiomeric excess was measured by GC or HPLC using a chiral column.


## 5. Synthesis of Co-<sup>Ph</sup>BPE complexes

- <sup>Ph</sup>BPE-Co(II)-OTf<sub>2</sub> complex:



*Scheme S 2 Co-complex synthesis*

In a glove box, (S,S)-BPE (0.2 mmol, 101 mg) and anhydrous Co(OTf)<sub>2</sub> (0.2 mmol, 73 mg) was dissolved in dry THF with a stirring bar. The reaction mixture was stirred overnight (16 h) which was turned into light pink solution. The solvent was removed and the solid was washed with ether and dried in Schlenk which afforded light violet powder. Elemental analysis C<sub>36</sub>H<sub>36</sub>CoF<sub>6</sub>O<sub>6</sub>P<sub>2</sub>S<sub>2</sub>: Calculated (%) C: 50.07, H: 4.20 S: 7.42; Observed (%) C: 50.26 H: 4.78 S: 7.038.




*Figure S 17 Experimental X-band EPR spectrum of isolated [S,S-<sup>Ph</sup>BPE]Co(OTf)<sub>2</sub>*


- [<sup>Ph</sup>BPE-Co(I)-Cl]<sub>2</sub> dimer **Co(I)-1** synthesis:

The [<sup>Ph</sup>BPE-Co(I)-Cl]<sub>2</sub> was synthesized according to the literature procedure via Zn-reduction. (Ref. M.

R. Friedfeld, H. Zhong, R. T. Ruck, M. Shevlin, P. J. Chirik, *Science* 2018, 360, 888. )




In a glove box, (S,S)-<sup>Ph</sup>BPECoCl<sub>2</sub> (0.125 mmol, 80 mg) and Zn dust <10 μm in size (0.6 mmol, 42 mg) was dissolved in dry THF and MeOH with a stirring bar. The reaction mixture was turned into a deep green solution and was stirred for 20 mins at room temperature. Then the solvent was removed and the solid was dissolved in THF and filtered under inert conditions and dried under the Schlenk line which afforded the desired [<sup>Ph</sup>BPE-Co(I)-Cl]<sub>2</sub> as dark green solid. Elemental analysis C<sub>68</sub>H<sub>72</sub>Cl<sub>2</sub>Co<sub>2</sub>P<sub>4</sub>: Calculated (%) C: 67.95, H: 6.04; Observed (%) C: 67.55, H: 6.26



▪ [<sup>Ph</sup>BPE-Co(benzene)]BAR<sup>F</sup><sub>4</sub>, Co(I)-2 synthesis:

The cationic Co(I) complex was synthesized according to the reported procedure.



Step-1: (Ref. Zhu, D.; Janssen, F. F. B. J.; Budzelaar, P. H. M. (Py)<sub>2</sub>Co(CH<sub>2</sub>SiMe<sub>3</sub>)<sub>2</sub>. *Organometallics* **2010**, 29 (8), 1897-1908.)

(Py)<sub>4</sub>CoCl<sub>2</sub>: Anhydrous CoCl<sub>2</sub> (1.36 g, 10.4 mmol) was transferred into a 100 mL Schlenk tube, and 15 mL of pyridine was added. The resulting suspension of initially blue solid in a pink solution was stirred


overnight at room temperature, during which the solid became pink. The solid was filtered off and dried in vacuo, giving 3.65 g (78%) of pink crude  $(\text{Py})_4\text{CoCl}_2$ . Elemental analysis for  $\text{C}_{20}\text{H}_{20}\text{Cl}_2\text{CoN}_4$ : Calculated (%) C, 53.83; H, 4.52; N, 12.56; Cl, 15.89; Observed (%) C, 53.67; H, 4.85; N, 12.81; Cl, 16.10.

Step-2: (Ref. Zhu, D.; Janssen, F. F. B. J.; Budzelaar, P. H. M. *Organometallics* **2010**, *29* (8), 1897-1908.)


**$(\text{Py})_2\text{CoCH}_2\text{TMS}$** : Synthesized as literature reported procedure. (Ref. Zhu, D.; Janssen, F. F. B. J.; Budzelaar, P. H. M. *Organometallics* **2010**, *29* (8), 1897-1908.)

**$[(R,R)\text{-}(\text{PhBPE})\text{Co}(\eta^6\text{-C}_6\text{H}_6)][\text{BArF}_4]$ : Co(I)-2** Synthesized according to literature procedure. (Ref. MacNeil, C. S.; Zhong, H.; Pabst, T. P.; Shevlin, M.; Chirik, P. J. *ACS. Catal.* **2022**, 4680-4687.)

In a glovebox, a 25 mL Schlenk was charged with  $(\text{py})_2\text{Co}(\text{CH}_2\text{SiMe}_3)_2$  (0.065 g, 0.17 mmol) as a dark green semisolid and dissolved in 2 mL of diethyl ether. In a separate flask,  $(R,R)$ -PhBPE (0.084 g, 0.17 mmol) was weighed and dissolved in diethyl ether. The  $(\text{py})_2\text{Co}(\text{CH}_2\text{SiMe}_3)_2$  solution was added dropwise to the  $(R,R)$ -PhBPE solution. Then the color of the mixture was changed to yellow. Finally,  $[(\eta^5\text{-C}_5\text{H}_5)_2\text{Fe}][\text{BArF}_4]$  (0.178 g, 0.17 mmol) was weighed out as a deep blue solid and dissolved in a mixture of diethyl ether and benzene (2:1) and added dropwise to the stirring ethereal solution of  $(R,R)$ -  $(\text{PhBPE})\text{Co}(\text{CH}_2\text{SiMe}_3)_2$  (formed in situ), the deep blue color instantly gave way to bright yellow. The reaction mixture was stirred for 15 minutes at ambient temperature. Volatiles were removed under reduced pressure and the residue was washed with pentane (x 2) to remove ferrocene and silane byproducts. The residue was dissolved in diethyl ether and filtered through cannula and dried under reduced pressure (88% yield) of  $[(R,R)\text{-}(\text{PhBPE})\text{Co}(\eta^6\text{-C}_6\text{H}_6)][\text{BArF}_4]$  as bright yellow crystalline solid. Elemental analysis for  $\text{C}_{72}\text{H}_{54}\text{BCoF}_{24}\text{P}_2$ , : Calculated (%) C, 57.39; H, 3.61. Observed (%) C, 57.56; H, 3.48.



- **<sup>Ph</sup>BPE-Co(I)-OTf , Co(I)-3 complex:**




In a glove box, (S,S)-<sup>Ph</sup>BPECoOTf<sub>2</sub> (0.115 mmol, 100 mg) and Zn dust <10 μm in size (0.15 mmol, 11 mg) was dissolved in dry THF and MeOH with a stirring bar. The reaction mixture was stirred for 1h mins at room temperature. Then the solvent was removed and the solid was dissolved in THF and filtered under inert conditions and dried under the Schlenk line which afforded the desired <sup>Ph</sup>BPE-Co(I)-OTf as light red solid. Elemental analysis C<sub>35</sub>H<sub>36</sub>CoF<sub>3</sub>O<sub>2</sub>P<sub>2</sub>S: Calculated (%) C: 58.83, H: 5.08; Observed (%) C: 58.69, H: 5.26.

## 6. EPR experiments for mechanistic studies

In a prototypical measurement the sample have been prepared following different reaction set up in order to mimic the active catalytic conditions, which have been depicted as follows:

- **Experiment 1:**



Scheme S 3 Experiment-1

[Co(OTf)<sub>2</sub>] (3.6 mg) and (S,S)-<sup>Ph</sup>BPE(5.4 mg) were stirred for 10-15 mins in 2-MeTHF (2mL) at room temperature followed by the addition of Zn (5-6 mg). Then the vial was transferred into a autoclave and pressurized with 10 bar

SI-23





Figure S 18 Experimental X-band EPR spectrum

of H<sub>2</sub> and stirred the precatalyst for 1 h at 50°C. After that the reaction mixture was transferred into a EPR tube and immediately iced in liquid nitrogen and subjected to the EPR analysis.

▪ **Experiment 2:**



Scheme S 4 Experiment-2

[Co(OTf)<sub>2</sub>] (3.6 mg) and (S,S)-<sup>Ph</sup>BPE(5.4 mg) were stirred for 10-15 mins in 2-MeTHF (2mL) at room temperature followed by the addition of Zn (5-6 mg) and substrate 1a (0.2 mmol). Then the vial was transferred into a autoclave and pressurized with 10 bar of H<sub>2</sub> and stirred the precatalyst for 2 h at 50°C. After that the reaction mixture was transferred into a EPR tube and immediately iced in liquid nitrogen and subjected to the EPR analysis.





Figure S 19 Experimental X-band EPR spectrum

▪ **Eperiment 3:**



Scheme S 5 Experiment-3

[Co(OTf)<sub>2</sub>] (3.6 mg) and (S,S)-<sup>Ph</sup>BPE(5.4 mg) were stirred for 10-15 mins in 2-MeTHF (2mL) at room temperature followed by the addition of Zn (5-6 mg) and substrate 1a (0.2 mmol). The catalytic mixture was for 1.5 h at 50°C. After that the reaction




Figure S 20 Experimental X-band EPR spectrum



mixture was transferred into a EPR tube and immediately iced in liquid nitrogen and subjected to the EPR analysis.





Figure S 21 Experimental X-band EPR spectrum comparison following catalytic conditions

## 7. Analytical data of the indanone-amides

- ***N*-(2,3-dihydro-1H-inden-1-yl)acetamide**



**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ; 7.31-7.20 (m, 4H), 5.64 (br, 1H), 5.52-5.44 (m, 1H), 3.03-2.81 (m, 2H), 2.66-2.55 (m, 1H), 2.03 (s, 3H), 1.89-1.76 (2H).

**<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ; 167.89, 141.55, 141.22, 126.11, 124.87, 122.92, 122.10, 75.54, 75.11, 74.69, 52.86, 32.17, 28.31, 21.55.

HRMS: m/z calculated for C<sub>11</sub>H<sub>13</sub>NO: 176.26 [M+H]<sup>+</sup>; observed 176.23




Figure S 22 <sup>1</sup>H NMR of 1b





Figure S 23  $^{13}\text{C}$  NMR of 1b

▪ *N*-(6-methoxy-2,3-dihydro-1H-inden-1-yl)acetamide



$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.11 (d,  $J = 8.09$  Hz, 1H), 6.84-6.75 (m, 2H), 5.84 (br, 1H), 5.42 (q,  $J = 7.74$  Hz, 1H), 3.77 (s, 3H), 2.94-2.71 (m, 2H), 2.62-2.51 (m, 1H), 2.01 (s, 3H), 1.85-1.73 (m, 1H).

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.86, 159.08, 144.60, 135.26, 125.37, 114.40, 108.96, 55.54, 54.87, 34.54, 29.37, 23.43.

HRMS:  $m/z$  calculated for  $\text{C}_{12}\text{H}_{15}\text{NO}_2$ : 206.34  $[\text{M}+\text{H}]^+$ ; observed 206.37




Figure S 24 <sup>1</sup>H NMR of 4b





Figure S 25 <sup>13</sup>C NMR of 4b

▪ *N*-(5-methoxy-2,3-dihydro-1*H*-inden-1-yl)acetamide



$^1\text{H NMR}$  (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.18 (d,  $J = 7.97$  Hz), 6.77-6.72 (m, 2H), 5.75 (br, 1H), 5.38 (q,  $J = 7.50$  Hz, 1H), 3.78 (s, 3H), 2.99-2.79 (m, 2H), 2.62-2.53 (m, 1H), 2.00 (s, 3H), 1.87-1.77 (m, 1H).

$^{13}\text{C NMR}$  (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.82, 160.01, 145.25, 135.20, 124.83, 112.93, 109.91, 55.46, 54.20, 34.36, 30.41, 23.45.

**HRMS:**  $m/z$  calculated for  $\text{C}_{12}\text{H}_{15}\text{NO}_2$ : 206.37  $[\text{M}+\text{H}]^+$ ; observed 206.31




Figure S 26  $^1\text{H NMR}$  of 5b





Figure S 27  $^{13}\text{C}$  NMR of 5b

▪ *N*-(5-fluoro-2,3-dihydro-1H-inden-1-yl)acetamide



$^1\text{H}$  NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.23-7.19 (m, 1H), 6.93-6.85 (m, 2H), 5.73 (br, 1H), 5.40 (q,  $J$  = 7.68 Hz, 1H), 3.00-2.78 (m, 2H), 2.64-2.53 (m, 1H), 2.01 (s, 3H), 1.89-1.76 (m, 1H).

$^{13}\text{C}$  NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ : 169.87, 161.39, 145.77, 145.65, 138.74, 125.29, 125.17, 113.99, 113.69, 111.87, 111.58, 77.25, 54.03, 34.35, 30.25, 30.22, 23.40.

HRMS:  $m/z$  calculated for C<sub>11</sub>H<sub>12</sub>FNO: 194.36 [M+H]<sup>+</sup>; observed 194.39




Figure S 28  $^1\text{H}$  NMR of 6b




Figure S 29  $^{13}\text{C}$  NMR of 6b





Figure S 30  $^{19}\text{F}$  NMR of 6b

▪ ***N*-(5-bromo-2,3-dihydro-1H-inden-1-yl)acetamide**



$^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.37 (s, 1H), 7.34-7.30 (m, 1H), 7.14 (d,  $J = 8.00$  Hz, 1H), 5.68 (br, 1H), 5.41 (1,  $J = 7.82$  Hz, 1H), 3.00-2.79 (m, 2H), 2.63-2.52 (m, 1H), 2.02 (s, 3H), 1.86-1.73 (m, 1H).

$^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 169.85, 145.69, 142.29, 129.90, 128.00, 125.57, 121.91, 54.22, 34.06, 30.06, 23.42.

**HRMS:**  $m/z$  calculated for  $\text{C}_{11}\text{H}_{12}\text{BrNO}$ : 255.16  $[\text{M}+\text{H}]^+$  ; observed 255.18






Figure S 31 <sup>1</sup>H NMR of 7b





Figure S 32 <sup>13</sup>C NMR of 7b

▪ ***N*-(2,3-dihydro-1*H*-inden-1-yl)isobutyramide**



**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ: .25-7.19 (m, 3H), 5.65 (br, 1H), 5.49 (1, J = 7.888 Hz, 1H), 3.03- 2.81 (m, 2H), 2.65-2.55 (m, 1H), 2.42-2.33 (m, 1H), 1.83-1.72 (m, 1H), 1.21-1.17 (d, J = 11.92 Hz, 6H).

**<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ; 176.77, 143.44, 127.93, 126.79, 124.82, 123.92, 54.38, 35.76, 34.16, 30.22, 19.81, 19.61.

**HRMS:** m/z calculated for C<sub>13</sub>H<sub>17</sub>NO:204.23 [M+H]<sup>+</sup> ; observed 204.29




Figure S 33 <sup>1</sup>H NMR of 2b





Figure S 34  $^{13}\text{C}$  NMR of 2b

▪ *N*-(2,3-dihydro-1H-inden-1-yl)benzamide



$^1\text{H}$  NMR (Xxx MHz, CDCl<sub>3</sub>)  $\delta$ ; 7.82-7.77 (m, 2H), 7.54-7.35 (m, 4H), 7.29-7.20 (m, 3H), 6.36 (br, 1H), 5.71 (q,  $J=7.69$  Hz, 1H), 3.09-2.88 (m, 2H), 2.77-2.66 (m, 1H), 1.99-1.87 (m, 1H).

$^{13}\text{C}$  NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ ; 167.24, 143.61, 143.15, 134.52, 131.55, 128.62, 128.13, 126.96, 126.89, 124.94, 124.14, 55.19, 34.23, 30.35.

HRMS:  $m/z$  calculated for C<sub>16</sub>H<sub>15</sub>NO:238.39 [M+H]<sup>+</sup>; observed 238.41




Figure S 35  $^1\text{H}$  NMR of **3b**






Figure S 3b

## 8. Synthetic protocol for Rasagiline synthesis




Scheme 5 Azilect synthesis via C-catalyzed asymmetric hydrogenation

- *Step-a* (Co-catalyzed asymmetric hydrogenation of **1a**):



The hydrogenation experiments were performed in a stainless steel autoclave charged with an insert suitable for up to 5 reaction vessels (7 mL) with teflon mini stirring bars. A reaction vessel is charged with [Co]-precursors (5 mol%) and ligand (5 mol%) and stirred for 10-15 mins in the 2-Me THF (5mL). Then the additive Zn (50 mol%) and desired substrates **1a** (1.0 mmol) were added to the reaction vessel maintaining the inert atmosphere and the vessels were placed in the autoclave. The autoclave was purged two times with nitrogen and three times with hydrogen. Finally it was pressurized at the 20 bar  $\text{H}_2$  pressure at  $50^\circ\text{C}$  for 22 h. After the required reaction time, the autoclave was depressurized and the reaction vessels were diluted with EtOAc and filtered through a short pad of silica (96% isolated yield). The conversion was determined by GC, GC-MS and NMR measurement and the enantiomeric excess was measured by GC or HPLC using a chiral column.

- *Step-b (deacylation of 1b)*



Potassium carbonate,  $K_2CO_3$  (3.0 mmol) was added to the MeOH/H<sub>2</sub>O (1:1) solution of amide (1.5 mmol) and stirred for 25 hrs at 50°C. After that, the reaction mixture was concentrated in vacuum and extracted in solution of DCM and saturated sodium bicarbonate solution. The organic layer was separated and washed with brine and dried over  $MgSO_4$  and concentrated to result the corresponding amine in 89% yield without the loss of optical purity (89% isolated yield).

**<sup>1</sup>H NMR** (300 MHz,  $CDCl_3$ )  $\delta$ ; 7.35-7.32 (m, 1H), 7.24-7.19 (m, 3H), 4.38-4.33 (m, 1H), 3.01-2.93 (m, 1H), 2.85-2.77 (m, 1H), 2.56-2.47 (m, 1H), 1.74-1.64 (m, 3H).

**<sup>13</sup>C NMR** (75 MHz,  $CDCl_3$ )  $\delta$ ; 147.49, 143.12, 127.19, 126.50, 124.69, 123.32, 57.31, 37.40, 30.13.

$[\alpha]_D^{298} = -15.4^\circ$  (c 1.5, *methanol*)




Figure S 36 <sup>1</sup>H NMR of 1c





Figure S 37 <sup>13</sup>C NMR of 1c

- *Step-c (propargylation of 1c)*



Potassium carbonate (1.1 eqv) was added to the solution of **1c** (1 eq.) in 10 mL in acetonitrile. Propargyl bromide (1.05 eq.) was added to the reaction mixture and stirred at 30°C for 12 h. The solid was filtered off and solvent was removed. The residue was further purified via flash column (EtOAc: Hexane, 30%) as yellow oil in 81% yield (98% ee).

**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ; 7.37-7.33 (m, 1H), 7.26-7.18 (m, 3H), 4.38 (t, 1H, J= 6.7 Hz), 3.53 (dd, 2H, J=2.4 Hz), 3.10-3.00 (m, 1H), 2.88-2.78 (m, 1H), 2.46-2.34 (m, 1H), 2.26 (t, 1H, J= 2.45 Hz), 1.91-1.81 (m, 1H), 1.65 (s, 1H).

**<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ; 144.52, 143.84, 127.66, 126.28, 124.89, 124.21, 82.51, 71.43, 61.90, 36.19, 33.35, 30.48.

$[\alpha]_D^{298} = +17.9^\circ$  (c 0.2, chloroform)

**HRMS:** m/z calculated for C<sub>12</sub>H<sub>14</sub>N: 172.2490 [M+H]<sup>+</sup>; observed 172.2468

**HPLC:** Cellulose-3






Figure S 38 <sup>1</sup>H NMR of **1d**





Figure S 39 <sup>13</sup>C NMR of **1d**

## 9. Deuteration of **1a** and analytical data



*Scheme S 6 Asymmetric deuteration of **1a** using Co/BPE precatalyst*

Protocol for deuteration:

The deuteration experiment was performed in a stainless steel autoclave charged with an insert suitable for up to 8 reaction vessels (4 mL) with teflon mini stirring bars. In the experiment, a reaction vessel is charged with [Co (OTf)<sub>2</sub>]-precursor (5 mol%) and (*S,S*)-<sup>Ph</sup>BPE (5 mol%) and stirred for 10-15 mins in 2-Me THF (2mL). Then the additive Zn (50 mol%) and desired substrates **1a** (0.5 mmol) were added to the reaction vessel maintaining the inert atmosphere and the vessels were placed in the autoclave. The autoclave was purged two times with nitrogen. Finally it was pressurized at the 15 bar of D<sub>2</sub> pressure at 50°C for 20 h. After that, the autoclave was depressurized and the reaction vessels were diluted with EtOAc and filtered through a short pad of silica. The conversion was determined by GC and GC-MS measurement. The *d*-incorporation was analysed via NMR analysis (95% isolated yield).




Figure S 40 <sup>1</sup>H NMR of 1b-d<sub>2</sub>




Figure S 41 <sup>13</sup>C NMR of 1b-d<sub>2</sub>




Figure S 42  $^1\text{H}$  NMR Hydrogen vs Deuteration experiments of **1a**




Figure S 43  $^{13}\text{C}$  NMR Hydrogen vs Deuteration experiments of **1a**




Figure S 44  $^1\text{H}$  NMR of  $1b\text{-}d_2$  (snapshot with characteristic peak region)





Figure S 45 Possible pathway of the hydrogenation of  $1a$

## 10. Chiral HPLC traces





```

=====
Acq. Operator   : Analytik                      Seq. Line :    5
Acq. Instrument : LCS                          Location  : Vial 1
Injection Date  : 4/13/2023 8:21:56 PM         Inj       :    1
                                                Inj Volume: 0.2 µl

Acq. Method    : C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/13/2023 12:39:49 PM by Analytik
Analysis Method: C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/14/2023 9:58:52 AM by Analytik
                (modified after loading)
Method Info    : OD-H, Hept./EtOH 90:10, 0.3ml/min
  
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.067	BB	0.3994	4192.35938	159.12187	50.1585
2	21.682	BB	0.5460	4165.86035	116.84090	49.8415

Totals : 8358.21973 275.96278


Figure S 46 HPLC trace of rac-4b

```

=====
Acq. Operator   : Analytik                      Seq. Line :    4
Acq. Instrument : LCS                          Location  : Vial 2
Injection Date  : 4/13/2023 7:25:53 PM         Inj       :    1
                                           Inj Volume: 0.2 µl

Acq. Method    : C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/13/2023 12:39:49 PM by Analytik
Analysis Method: C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/14/2023 9:58:52 AM by Analytik
                (modified after loading)
Method Info    : OD-H, Hept./EtOH 90:10, 0.3ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [MAU]	Area %
1	13.053	FM	0.4941	2495.70776	84.18707	94.7734
2	21.722	MM	0.5046	137.63455	4.54607	5.2266

Totals :                    2633.34232    88.73314

Figure S 47 HPLC trace of enantioenriched-4b







```

=====
Acq. Operator   : Analytik                      Seq. Line :    1
Acq. Instrument : LC5                          Location  : Vial 2
Injection Date  : 4/4/2023 9:58:35 AM          Inj       :    1
                                                    Inj Volume: 1.0 µl

Acq. Method     : C:\CHEM32\1\METHODS\OD-H0.3.M
Last changed    : 4/4/2023 9:57:57 AM by Analytik
Analysis Method : C:\CHEM32\1\METHODS\OD-H0.3.M
Last changed    : 4/4/2023 4:00:52 PM by Analytik
                  (modified after loading)
Method Info     : OD-H, Hept./EtOH 95:5, 0.3ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.233	BB	0.7517	7200.00879	144.40715	50.0830
2	32.460	BB	0.8503	7176.14990	124.16216	49.9170

Totals :                            1.43762e4    268.56931

Figure S 48 HPLC trace of rac-5b



```

=====
Acq. Operator   : Analytik                      Seq. Line :    2
Acq. Instrument : LC5                          Location  : Vial 12
Injection Date  : 4/4/2023 10:44:41 AM         Inj       :    1
                                                Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\OD-H0.3.M
Last changed   : 4/4/2023 9:57:57 AM by Analytik
Analysis Method: C:\CHEM32\1\METHODS\OD-H0.3.M
Last changed   : 4/4/2023 4:02:08 PM by Analytik
                (modified after loading)
Method Info    : OD-H, Hept./EtOH 95:5, 0.3ml/min
=====

```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====


```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	26.275	BB	0.7996	4.91942e4	938.46130	91.0037
2	32.645	MM	0.9475	4863.16650	85.54361	8.9963

Totals :                    5.40574e4  1024.00491

Figure S 49 HPLC trace of enantioenriched-5b




```

=====
Acq. Operator   : Analytik                      Seq. Line :    6
Acq. Instrument : LCS                          Location  : Vial 11
Injection Date  : 4/12/2023 8:28:59 PM         Inj       :    1
                                           Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\OJ-H.M
Last changed   : 4/12/2023 4:15:30 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\OJ-H.M
Last changed   : 4/13/2023 9:32:26 AM by Analytik
                (modified after loading)
Method Info    : OJ-H, Hept./EtOH 98:2, 2ml/min
=====

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	21.858	BB	0.5439	917.46997	24.55559	49.8467
2	30.579	BB	0.6184	923.11475	18.24245	50.1533

Totals :                    1840.58472    42.79804

Figure S 50 HPLC trace of rac-6b


```

=====
Acq. Operator   : Analytik                      Seq. Line :    8
Acq. Instrument : LC5                          Location  : Vial 21
Injection Date  : 4/12/2023 10:41:07 PM       Inj       :    1
                                                Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\OJ-H.M
Last changed   : 4/12/2023 4:15:30 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\OJ-H.M
Last changed   : 4/13/2023 9:32:26 AM by Analytik
                (modified after loading)
Method Info    : OJ-H, Hept./EtOH 98:2, 2ml/min
=====

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs


```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [MAU*s]	Height [MAU]	Area %
1	22.210	MM	0.6124	358.22171	9.74888	10.0274
2	30.849	MM	0.8601	3214.20923	62.28588	89.9726

Totals :                            3572.43094    72.03476

Figure S 51 HPLC trace of enantioenriched-6b





```

=====
Acq. Operator   : Analytik                      Seq. Line :    4
Acq. Instrument : LC5                          Location  : Vial 12
Injection Date  : 4/12/2023 6:16:50 PM          Inj       :    1
                                           Inj Volume: 1.0 µl

Acq. Method     : C:\CHEM32\1\METHODS\OJ-H.M
Last changed    : 4/12/2023 4:15:30 PM by Analytik
                  (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\OJ-H.M
Last changed    : 4/13/2023 9:32:26 AM by Analytik
                  (modified after loading)
Method Info     : OJ-H, Hept./EtOH 98:2, 2ml/min
=====

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	36.790	MM	1.1008	1786.29065	27.04559	50.3908
2	53.141	MM	1.6715	1758.58386	17.53542	49.6092

Totals :                    3544.87451    44.58101

Figure S 52 HPLC trace of rac-7b


```

=====
Acq. Operator   : Analytik                      Seq. Line :    2
Acq. Instrument : LC5                          Location  : Vial 22
Injection Date  : 4/12/2023 4:04:40 PM         Inj       :    1
                                           Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\0J-H.M
Last changed   : 4/12/2023 4:15:30 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\0J-H.M
Last changed   : 4/13/2023 9:32:26 AM by Analytik
                (modified after loading)
Method Info    : 0J-H, Hept./EtOH 98:2, 2ml/min
=====

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs


```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	36.036	BB	0.7318	870.04547	14.06362	20.9967
2	51.411	MM	1.5516	3273.68555	35.16568	79.0033

Totals :                    4143.73102    49.22931

Figure S 53 HPLC trace of enantioenriched-7b





```

=====
Acq. Operator   : Analytik                      Seq. Line :    5
Acq. Instrument : LCS                          Location  : Vial 11
Injection Date  : 2/8/2023 8:25:14 PM          Inj       :    1
                                                    Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\AD-H.M
Last changed   : 2/8/2023 4:22:23 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\AD-H.M
Last changed   : 2/9/2023 2:31:19 PM by Analytik
                (modified after loading)
Method Info    : AD-H, Hept./EtOH 95:5, 1ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
 Area Percent Report  
 =====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.853	BB	0.2751	4935.68701	278.06674	50.0328
2	8.387	BB	0.3416	4929.20898	223.23030	49.9672

Totals :                      9864.89600   501.29704



Figure S 54 HPLC trace of rac-2b

```

=====
Acq. Operator   : Analytik                      Seq. Line :    4
Acq. Instrument : LC5                          Location  : Vial 22
Injection Date  : 2/8/2023 7:03:06 PM          Inj       :    1
                                                    Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\AD-H.M
Last changed   : 2/8/2023 4:22:23 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\AD-H.M
Last changed   : 2/9/2023 2:31:19 PM by Analytik
                (modified after loading)
Method Info    : AD-H, Hept./EtOH 95:5, 1ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```


Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.825	MM	0.2916	3157.96143	180.48326	94.0081
2	8.353	MM	0.3466	201.28401	9.67893	5.9919

Totals :                    3359.24544  190.16219

Figure S 55 HPLC trace of enantioenriched-2b







```

=====
Acq. Operator   : Analytik                      Seq. Line :    8
Acq. Instrument : LC5                          Location  : Vial 3
Injection Date  : 4/3/2023 4:32:08 PM          Inj       :    1
                                           Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/3/2023 2:16:18 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/4/2023 9:19:16 AM by Analytik
                (modified after loading)
Method Info    : OD-H, Hept./EtOH 95:5, 1ml/min
  
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.166	BB	0.2785	1108.99890	60.31322	49.9537
2	13.890	BB	0.4792	1111.05420	34.91668	50.0463

Totals : 2220.05310 95.22990



Figure S 56 HPLC trace of rac-3b

```

=====
Acq. Operator   : Analytik                      Seq. Line :    7
Acq. Instrument : LC5                          Location  : Vial 11
Injection Date  : 4/3/2023 3:00:01 PM          Inj       :    1
                                                Inj Volume: 1.0 µl
Different Inj Volume from Sequence ! Actual Inj Volume : 0.2 µl
Acq. Method    : C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/3/2023 2:16:18 PM by Analytik
                (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\OD-H.M
Last changed   : 4/4/2023 9:19:16 AM by Analytik
                (modified after loading)
Method Info    : OD-H, Hept./EtOH 95:5, 1ml/min
=====

```

Additional Info : Peak(s) manually integrated



Area Percent Report

```


=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====

```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.993	BB	0.2649	2282.30176	129.97195	96.9581
2	13.635	MM	0.3516	71.60250	3.39449	3.0419

Figure S 57 HPLC trace of enantioenriched-3b




```

=====
Acq. Operator   : Analytik                      Seq. Line :    5
Acq. Instrument : LC5                          Location  : Vial 1
Injection Date  : 5/5/2023 1:53:33 PM          Inj       :    1
                                                Inj Volume: 1.0 µl
Different Inj Volume from Sequence ! Actual Inj Volume : 3.0 µl
Acq. Method    : C:\CHEM32\1\METHODS\CELLULOSE4.M
Last changed   : 5/5/2023 1:08:04 PM by Analytik
                (modified after loading)
Analysis Method : C:\CHEM32\1\METHODS\CELLULOSE4.M
Last changed   : 5/5/2023 3:30:17 PM by Analytik
                (modified after loading)
Method Info    : AS-H , Hept./EtOH 90:10, 1ml/min
=====

```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====

```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.150	BB	0.7584	4205.29346	82.53555	50.8551
2	15.928	BB	0.7850	4063.86719	68.21700	49.1449


Figure S 58 HPLC trace of rac-1c

```

=====
Acq. Operator   : Analytik                      Seq. Line :    4
Acq. Instrument : LC5                          Location  : Vial 2
Injection Date  : 5/5/2023 1:07:28 PM          Inj       :    1
                                                Inj Volume: 1.0 µl

Acq. Method    : C:\CHEM32\1\METHODS\CELLULOSE4.M
Last changed   : 5/5/2023 1:08:04 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\CELLULOSE4.M
Last changed   : 5/5/2023 3:30:17 PM by Analytik
                (modified after loading)
Method Info    : AS-H , Hept./EtOH 90:10, 1ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```


Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.941	BB	0.6236	4553.72607	109.39518	100.0000

Totals :                                   4553.72607  109.39518

Figure S 59 HPLC trace of enantioenriched-1c





```

=====
Acq. Operator   : Analytik                      Seq. Line :    2
Acq. Instrument : LCS                          Location  : Vial 11
Injection Date  : 4/11/2023 12:31:11 PM        Inj       :    1
                                           Inj Volume: 0.2 µl

Acq. Method    : C:\CHEM32\1\METHODS\CELLULOSE3.M
Last changed   : 4/11/2023 12:27:12 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\CELLULOSE3.M
Last changed   : 4/11/2023 2:16:15 PM by Analytik
                (modified after loading)
Method Info    : Cellulose 3 , Hept./EtOH 95:0,5, 0.5ml/min
=====

```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
=====

```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.319	BB	0.1769	476.05875	41.16010	50.1582
2	9.885	BB	0.2139	473.05508	34.09518	49.8418

Totals :                                    949.11383    75.25528


Figure S 60 HPLC trace of rac-1d

```

=====
Acq. Operator   : Analytik                      Seq. Line :    4
Acq. Instrument : LCS                          Location  : Vial 12
Injection Date  : 4/11/2023 1:23:16 PM         Inj       :    1
                                                Inj Volume: 0.2 µl

Acq. Method    : C:\CHEM32\1\METHODS\CELLULOSE3.M
Last changed   : 4/11/2023 12:56:54 PM by Analytik
                (modified after loading)
Analysis Method: C:\CHEM32\1\METHODS\CELLULOSE3.M
Last changed   : 4/11/2023 2:18:24 PM by Analytik
                (modified after loading)
Method Info    : Cellulose 3 , Hept./EtOH 95:0,5, 0.5ml/min
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 C, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.240	MM	0.1749	132.00711	12.57682	0.9017
2	9.705	BB	0.2168	1.45082e4	1014.97113	99.0983

Totals :                    1.46402e4  1027.54795

Figure S 61 HPLC trace of enantioenriched-1d




```

-----
Acq. Operator   : SYSTEM                      Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                     Location  : 1 (F)
Injection Date  : 2/21/2023 3:08:41 PM        Inj       :    1
                                                Inj Volume: 1 µl

Acq. Method    : D:\ChemStation\1\Data\DEF_GC 2023-02-21 15-06-34\alpha-enamide_FID-m1.M
Last changed   : 10/21/2022 10:09:04 AM by SYSTEM
Analysis Method: D:\ChemStation\1\Data\DEF_GC 2023-02-21 15-06-34\alpha-enamide_FID-m1.M (
Sequence Method)
Last changed   : 4/15/2023 4:37:13 PM by SYSTEM
                (modified after loading)
Method Info    : alpha-enamide-AH

Sample Info    : SDC-RH-562
  
```

Additional Info : Peak(s) manually integrated



-----  
Area Percent Report  
-----

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution      : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 8, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	22.664	MM	0.2157	16.09205	1.24332	9.69653
2	23.981	MM	0.2488	149.86482	10.37094	90.30347

Totals :                                    165.95688    11.61426

Figure S 63 Chiral GC trace of enantioenched-1b



```


=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                    Location  :    2 (F)
Injection Date  : 2/21/2023 5:58:01 PM      Inj       :    1
                                                Inj Volume: 1 µl

Acq. Method    : D:\ChemStation\1\Data\DEF_GC 2023-02-21 17-55-58\alpha-enamide_FID-m1.M
Last changed   : 10/21/2022 10:09:04 AM by SYSTEM
Analysis Method: D:\ChemStation\1\Data\DEF_GC 2023-02-21 17-55-58\alpha-enamide_FID-m1.M (
Sequence Method)
Last changed   : 4/15/2023 4:38:16 PM by SYSTEM
                (modified after loading)
Method Info    : alpha-enamide-AH

Sample Info    : SDC-RH-563

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: FID1 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	22.687	NM	0.1903	6.08577	5.32949e-1	6.64910
2	23.925	NM	0.2508	85.44192	5.67737	93.35090


Totals :                    91.52768    6.21032

Figure S 64 Chiral GC trace of enantioencihed-1b

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                    Location  :    1 (F)
Injection Date  : 4/2/2023 12:04:03 PM      Inj       :    1
                                           Inj Volume: 1 µl
Acq. Method     : D:\ChemStation\1\Data\DEF_GC 2023-04-02 12-01-51\alpha-enamide_FID-m1.M
Last changed    : 10/21/2022 10:09:04 AM by SYSTEM
Analysis Method : D:\ChemStation\1\Data\DEF_GC 2023-04-02 12-01-51\alpha-enamide_FID-m1.M (
                  Sequence Method)
Last changed    : 4/2/2023 3:16:20 PM by SYSTEM
                  (modified after loading)
Method Info     : alpha-enamide-AH
Sample Info     : SDC-1a-R-amide
  
```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	23.859	BB	0.1987	127.26900	9.01262	1.000e2
Totals :				127.26900	9.01262	

Figure S 65 Chiral GC trace of enantioenched-1b (recrystallized)


```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                    Location  :    2 (F)
Injection Date  : 4/2/2023 1:02:59 PM        Inj       :    1
                                                Inj Volume: 1 µl

Acq. Method     : D:\ChemStation\1\Data\DEF_GC 2023-04-02 12-01-51\alpha-enamide_FID-m1.M
Last changed    : 10/21/2022 10:09:04 AM by SYSTEM
Analysis Method : D:\ChemStation\1\Data\DEF_GC 2023-04-02 12-01-51\alpha-enamide_FID-m1.M (
                  Sequence Method)
Last changed    : 4/2/2023 3:19:01 PM by SYSTEM
                  (modified after loading)
Method Info     : alpha-enamide-AH

Sample Info     : SDC-1a-S-amide
  
```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

=====
Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: FID1 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	22.603	BB	0.1928	168.32930	11.91964	1.000e2

Totals :                      168.32930    11.91964


Figure S 66 Chiral GC trace of enantioenched-1b (recrystallized)

```

=====
Acq. Operator   : SYSTEM                               Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                             Location  :    1 (F)
Injection Date  : 6/30/2023 1:28:56 PM                 Inj       :    1
                                                    Inj Volume: 1 µl
Acq. Method     : D:\ChemStation\1\Data\DEF_GC1 2023-06-30 13-26-00\alpha-enamide_FID-m1-N2-a
.M
Last changed    : 6/30/2023 1:25:32 PM by SYSTEM
Analysis Method : D:\ChemStation\1\Data\DEF_GC1 2023-06-30 13-26-00\alpha-enamide_FID-m1-N2-a
.M (Sequence Method)
Last changed    : 7/3/2023 11:10:15 AM by SYSTEM
                (modified after loading)
Method Info     : alpha-enamide-AH
Sample Info     : SDC-RH-611-3

```

Additional Info : Peak(s) manually integrated



=====  
Area Percent Report  
=====

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution       :      1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: FID1 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	31.738	MM	0.2798	54.75732	3.26210	32.88563
2	33.862	MM	0.3133	111.75101	5.94448	67.11437

Totals :                                    166.50834    9.20658

=====  
\*\*\* End of Report \*\*\*


Figure S 67 Chiral GC trace of crude reaction using Co(I)-1 as precatalyst (as shown in Figure 7)

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                    Location  :    2 (F)
Injection Date  : 7/3/2023 11:07:44 AM      Inj       :    1
                                           Inj Volume: 1 µl
Acq. Method     : D:\ChemStation\1\Data\DEF_GC1 2023-07-03 11-05-40\alpha-enamide_FID-m1-N2-a
                                           .M
Last changed    : 6/30/2023 1:25:32 PM by SYSTEM
Analysis Method : D:\ChemStation\1\Data\DEF_GC1 2023-07-03 11-05-40\alpha-enamide_FID-m1-N2-a
                                           .M (Sequence Method)
Last changed    : 7/3/2023 12:34:04 PM by SYSTEM
                                           (modified after loading)
Method Info     : alpha-enamide-AH
Sample Info     : SDC-RH-616

```

Additional Info : Peak(s) manually integrated



Area Percent Report

```

=====
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: FID1 B, Back Signal

Peak #	RetTime [min]	Type	Width [min]	Area [pA*s]	Height [pA]	Area %
1	31.775	BB	0.1922	371.04453	22.88524	75.81038
2	33.920	MM	0.2919	118.39307	6.75964	24.18962

Totals : 489.43760 29.64488


\*\*\* End of Report \*\*\*

Figure S 68 Chiral GC trace of crude reaction using Co(I)-2 as precatalyst (as shown in Figure 7)

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    1
Sample Operator : SYSTEM
Acq. Instrument : GC 8890                    Location  :    1 (F)
Injection Date  : 7/3/2023 9:59:53 AM        Inj       :    1
                                           Inj Volume: 1 µl
Acq. Method     : D:\ChemStation\1\Data\DEF_GC1 2023-07-03 09-57-05\alpha-enamide_FID-m1-N2-a
.M
Last changed    : 6/30/2023 1:25:32 PM by SYSTEM
Analysis Method : D:\ChemStation\1\Data\DEF_GC1 2023-07-03 09-57-05\alpha-enamide_FID-m1-N2-a
.M (Sequence Method)
Last changed    : 7/3/2023 11:07:18 AM by SYSTEM
                 (modified after loading)
Method Info     : alpha-enamide-AH
Sample Info     : SDC-1indaone substrate

```



```

=====
                          Area Percent Report
=====

```

```

Sorted By      :      Signal
Multiplier     :      1.0000
Dilution      :      1.0000
Use Multiplier & Dilution Factor with ISTDs

```

Signal 1: FID1 B, Back Signal

Figure S 69 Chiral GC trace of substrate **1a**